Michael Eckstut, Author at Certara

Heartbreaking Works of Staggering Genius: Cardiac Safety for Oncology

2015年3月12日

I could give you some of facts and figures about cancer. Like the fact that the American Cancer Society estimates there will be 1,658,370 new cancer cases diagnosed and 589,430 cancer deaths in the US this year. Or that pancreatic cancer has only a 5-year survival rate of 5%. But, these statistics belie the heartbreaking reality … Continued

Fighting Superbugs: Supporting FDA Approval of a New Antibiotic

2015年2月6日

By Michael Eckstut

One of the most rewarding parts of leading Certara’s consulting services is recognizing how our work supports new drug approvals to positively impact patients’ health. In this blog post, I’ll discuss how Certara helped Cubist obtain FDA approval for Zerbaxa™ (ceftolozane/tazobactam), a new antibacterial drug to treat adults with complicated infections. The growing threat of … Continued

Author: Michael Eckstut